pembrolizumab based treatment for COVID-19 - living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

	breast cancer - adjuvant	breast cancer - HR positive	breast cancer - triple negative					breast cancer HER 2 negative

	breast cancer - adjuvant	la/mBC - HR positive	mBC - TNBC - L1 - all population	mBC - TNBC - L1 - PDL1 positive	mBC - TNBC - L2 - all population	mBC - TNBC - L2 - PDL1 positive	es-BC - TNBC - NA - all population	es-BC - HER2 negative - (neo)adjuvant (NA)
pembrolizumab based treatment
pembrolizumab alone	KEYNOTE-522	NCT03051659			KEYNOTE-119 ...	KEYNOTE-119 ... KEYNOTE-119 ...	KEYNOTE-522
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide								I-SPY2
pembrolizumab plus SoC			KEYNOTE-355 ...	KEYNOTE-355 ... KEYNOTE-355 ...

Study type: